An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Ardelyx, Inc. (ARDX) will report its First Quarter 2024 Financial Results on May 2, 2024, and hold a conference call at 4:30 p.m. Eastern Time to discuss financial performance and business updates. Investors can join the call by dialing (844) 481-2838 (domestic) or (412) 317-1858 (international) or access the webcast on the company's website.
Ardelyx, Inc. (ARDX) comunicherà i risultati finanziari del primo trimestre del 2024 il 2 maggio 2024 e terrà una conferenza telefonica alle 16:30, ora della costa orientale, per discutere delle prestazioni finanziarie e degli aggiornamenti aziendali. Gli investitori possono partecipare alla chiamata componendo il numero (844) 481-2838 (nazionale) o (412) 317-1858 (internazionale) oppure accedendo alla trasmissione web sul sito web della società.
Ardelyx, Inc. (ARDX) informará sobre sus Resultados Financieros del Primer Trimestre de 2024 el 2 de mayo de 2024 y realizará una conferencia telefónica a las 4:30 p.m. hora del Este para discutir el rendimiento financiero y las actualizaciones de la empresa. Los inversores pueden unirse a la llamada marcando el (844) 481-2838 (doméstico) o el (412) 317-1858 (internacional) o acceder a la transmisión en la web en el sitio web de la compañía.
Ardelyx, Inc. (ARDX)는 2024년 5월 2일에 2024년도 1분기 재무 결과를 발표하며, 동부 표준시로 오후 4시 30분에 재무 성과와 사업 업데이트에 대해 논의하기 위한 컨퍼런스 콜을 개최할 예정입니다. 투자자들은 (844) 481-2838 (국내) 또는 (412) 317-1858 (국제) 번호로 전화를 걸거나 회사 웹사이트에서 웹캐스트를 접속하여 참여할 수 있습니다.
Ardelyx, Inc. (ARDX) publiera ses résultats financiers du premier trimestre 2024 le 2 mai 2024 et organisera une conférence téléphonique à 16h30, heure de l'Est, pour discuter des performances financières et des mises à jour de l'entreprise. Les investisseurs peuvent rejoindre l'appel en composant le (844) 481-2838 (national) ou le (412) 317-1858 (international) ou accéder à la webdiffusion sur le site web de la société.
Ardelyx, Inc. (ARDX) wird seine Finanzergebnisse für das erste Quartal 2024 am 2. Mai 2024 veröffentlichen und um 16:30 Uhr Ostküstenzeit eine Telefonkonferenz abhalten, um über die finanzielle Leistung und Geschäftsaktualisierungen zu sprechen. Investoren können sich über die Nummern (844) 481-2838 (Inland) oder (412) 317-1858 (international) in die Konferenz einwählen oder den Webcast auf der Unternehmenswebsite abrufen.
Positive
None.
Negative
None.
Conference call scheduled for 4:30 p.m. Eastern Time
WALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 2, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2024.
To participate in the conference call, please dial (844) 481-2838 (domestic) or (412) 317-1858 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.
About Ardelyx Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
When will Ardelyx (ARDX) report its First Quarter 2024 Financial Results?
Ardelyx (ARDX) will report its First Quarter 2024 Financial Results on May 2, 2024.
What time is the conference call scheduled for discussing financial results?
The conference call to discuss financial results is scheduled for 4:30 p.m. Eastern Time on May 2, 2024.
How can investors join the conference call?
Investors can join the conference call by dialing (844) 481-2838 (domestic) or (412) 317-1858 (international) and asking to be joined into the Ardelyx (ARDX) call.
Where can the webcast of the conference call be accessed?
The webcast of the conference call can be accessed under the Investors section of Ardelyx's (ARDX) website at www.ardelyx.com.
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
